Viread

FEATURED ARTICLES ABOUT VIREAD - PAGE 2

NEW DELHI: US drug company Gilead Sciences has filed an appeal in the Indian Intellectual Property Appellate Board (IPAB) to challenge a recent order by an Indian Patent Office that rejected two patent claims for its best seller drug Viread (tenofovir disoproxil fumarate). In August, the Indian Patent Office in Delhi shot down two patents sought by the US firm for Viread after patient groups and Indian company Cipla challenged its patentability. After India ushered in the new patent regime in 2005, the government provides 20-year marketing exclusivity for patented products.

MUMBAI: Domestic pharma major Cipla is opposing US-based biotech major Gilead Sciences' patent application in India for anti-AIDS drug Viread. This is a unique situation, as Gilead has already licenced out marketingIndia.

MUMBAI: Matrix Laboratories has received tentative approval for its abbreviated new drug application Tenofovir Disoproxil Fumarate tablets of 300 mg from the US Food and Drug Administration under the President's Emergency Plan for AIDS Relief. The company is the first to get tentative approval for the generic of Gilead Sciences Inc's 300 mg Viread tablets. The company's ANDA was approved in less than six months and is the seventh under President's Emergency Plan for AIDS Relief in the last 12 months.

NEW DELHI: California-based Gilead Sciences Inc has allowed four Indian companies to make and sell low-cost versions of three of its new HIV drugs under a firstof-its-kind agreement between an innovator pharmaceutical firm and a United Nations-backed patent-sharing body. Under the licensing deal, Ranbaxy Laboratories , Matrix Laboratories